8 results
The Pathway of Heme Synthesis, Showing Pathway Intermediates and End-Product Regulation by Heme #Pathophys #Honc #Heme
Heme #Pathophys #Honc ... Heme #Synthesis #Porphyria ... #NEJM
Susceptibility Factors in Patients with Porphyria Cutanea Tarda #Honc #SusceptibilityFactors #Porphyria #CutaneaTarda #NEJM
Patients with Porphyria ... Cutanea Tarda #Honc ... SusceptibilityFactors #Porphyria ... #CutaneaTarda #NEJM
Principal Types of Porphyria in the United States and Europe #Diagnosis #Honc #Porphyria #Types #AcuteIntermittent #CutaneaTarda
Principal Types of Porphyria ... Europe #Diagnosis #Honc ... #Porphyria #Types ... #Skin #Urine #NEJM
Signaling Mechanism of PD-1 and PD-L1 and Inhibition of PD-1 Signaling in Microsatellite-Instability–High Cancers. MHC1 denotes
histocompatibility complex 1 #Pathophysiology ... #Honc #Pharm #PD1 ... MicrosatelliteInstability #NEJM
Hemorrhagic Shock Coagulopathy #Pathophysiology #Honc #Coagulopathy #HemorrhagicShock #NEJM
Coagulopathy #Pathophysiology ... #Honc #Coagulopathy ... HemorrhagicShock #NEJM
The Mechanism of Small Interfering RNA (siRNA) Therapy. Synthetic double-stranded RNA containing an ALAS1-specific sequence is
#Pathophys #Honc ... #Porphyria #siRNA ... #Therapy #NEJM
Hemolysis in Hereditary Spherocytosis. Panel A shows the structure of a normal red cell and a
#Pathophysiology ... #Honc #IM #Spherocytosis ... HereditarySpherocytosis #NEJM
Immunosuppressive Strategies for the Prevention or Treatment of Acute GVHD. Panel A shows several classic immunosuppressive
#Pathophysiology ... #IM #Honc #Pharm ... Immunosuppression #NEJM